Memantine (Axura)
Substance developed by the Merz research organization used to treat dementia and Alzheimer's Disease.
memantine.com - A new meta analysis of Memantine in moderate to severe ...
By the moderate stage, the symptoms are more pronounced and Alzheimer's ... RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer's disease (AD): a ...
Memantine - Wikipedia, the free encyclopedia
Although memantine is approved for treatment of moderate to severe Alzheimer's ... Memantine has been associated with a moderate decrease in clinical deterioration ...
memantine (Namenda) - drug class, medical uses, medication side effects ...
Specifies the medication memantine (Namenda), a drug used for the treatment of moderate to severe dementia of the Alzheimer's type.
Memantine in Moderate-to-Severe Alzheimer's Disease -- Research article ...
This New England Journal of Medicine study concludes antiglutamatergic treatment with memantine, an NMDA antagonist, reduced clinical deterioration in moderate-to ...
Memantine
... R, Stoffler A, et al, "Memantine in Moderate-to-Severe Alzheimer's Disease,"N ... Farlow MR, Grossberg GT, et al, "Memantine Treatment in Patients With Moderate ...
Fact Sheet: About Memantine
effectiveness of memantine in treating moderate to severe Alzheimer's disease: ... trials of memantine in mild to moderate Alzheimer's and another trial in treating ...
Facts:
Memantine is classified as an uncompetitive low-to-moderate affinity N-methyl-D ... effectiveness of memantine in treating moderate to severe Alzheimer's disease: ...
Memantine Helpful in Moderate-to-Severe Alzheimer's Disease
This antiglutamatergic drug is the first to reduce clinical deterioration, ... Discuss the effects of memantine in moderate-to-severe Alzheimer's disease. ...
Namenda (Memantine), Alzheimer's medication
Namenda (Memantine)is a medication used in the treatment of Alzheimer's. ... In a study of 28 weeks duration, 252 patients with moderate to severe probable ...
|
Login
|
Sitemap
|
Disclaimer
|
About CNSforum
|
Contact Us
Lundbeck Institute
Educational Resources
Clinical Resources
Patient Websites
Publications
Community
The primary efficacy measures were the Clinician’s Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) and the Alzheimer’s Disease Cooperative Study Activities of Daily Living Inventory modified for severe dementia (ADCS-ADLsev).Memantine in moderate-to-severe Alzheimer's diseas...[N Engl J Med.